ACHV
NASDAQAchieve Life Sciences Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks56+800%
2026-04-192026-10-11
Mix2590d
- Insider10(40%)
- Other6(24%)
- Leadership4(16%)
- SEC Filings3(12%)
- Analyst2(8%)
Latest news
25 items- PRLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board has determined that Mr. Farrow is independent under Nasdaq listing rules. "Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through su
- PRAchieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsSEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve’s executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline. Tuson has spent 15 years building, launching, and scaling brands across the healthcare indust
- INSIDERSEC Form 4 filed by Achieve Life Sciences Inc.4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 3 filed by Achieve Life Sciences Inc.3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- PRAchieve Life Sciences Announces Granting of New Hire Inducement AwardsSEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit ("RSU") awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to Benjamin Halladay, the Company’s newly appointed
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Appoints Benjamin Halladay as Chief Financial OfficerSEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions. Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 millio
- ANALYSTStifel initiated coverage on Achieve Life Sciences with a new price targetStifel initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $18.00
- PRAchieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2026 Presentation Details Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL TrialSession: Top Late-Breaking Abst
- PRAchieve Life Sciences Announced Granting of New Hire Inducement AwardsSEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit ("RSU") awards covering an aggregate of 283,000 shares of its common stock for 7 new employees under Achieve’s 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve’s common stock on the grant date
- INSIDERDirector Stewart Richard Alistair sold $175,177 worth of shares (20,626 units at $8.49), decreasing direct ownership by 9% to 208,249 units (SEC Form 4)4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Achieve Life Sciences with a new price targetMorgan Stanley initiated coverage of Achieve Life Sciences with a rating of Overweight and set a new price target of $13.00
- SECSEC Form 10-Q filed by Achieve Life Sciences Inc.10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- SECAchieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
- PRAchieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesClosed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of
- PRAchieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and QualitySEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality. They join Achieve as the Company advances cytisinicline toward resubmission of its New Drug App
- PRAchieve Life Sciences Announced Granting of New Hire Inducement AwardsSEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve’s board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit ("RSU") awards covering an aggregate of 125,000 shares of its common stock for six new employees under Achieve’s 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve’s common stock on the grant d
- INSIDERSEC Form 4 filed by Director Sellig Thomas4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Royston Aaron4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Waldman Reid Alexander4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Stewart Richard Alistair4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Farrow Jeffrey S4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- INSIDERSEC Form 4 filed by Director Phelan Nancy R.4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
ACHV FAQ
6 questionsWhat does Achieve Life Sciences Inc. do?
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Where does ACHV stock trade?
Achieve Life Sciences Inc. (ACHV) is listed on NASDAQ.What sector and industry is ACHV in?
Achieve Life Sciences Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ACHV?
Achieve Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $1800.00 price target on 2026-09-30. Recent price targets range from $1200.00 to $2000.00.What companies are similar to ACHV?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare ACHV side-by-side with any of them on Quantisnow.How can I track ACHV on Quantisnow?
Quantisnow aggregates Achieve Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACHV to receive live email and push alerts on every new disclosure.